medigraphic.com

2023, Number 1

Next >>

Rev Hematol Mex 2023; 24 (1)

Hematological and renal alterations in patients with a diagnosis of Hodgkin's lymphoma receiving chemotherapy

Martínez-Sánchez LM, Vásquez-Estrada V, Morales-Montoya A, Cuartas-Agudelo YS, Vergara-Yáñez D, Roldán-Isaza M, Herrera-Almanza L, Roldán-Tabares MD, Gálvez-Cárdenas KM, Arias-Correa RH

Language: Spanish
References: 22
Page: 1-7
PDF size: 248.25 Kb.


ABSTRACT

Objective: To know the hematological and renal alterations that occur in patients with Hodgkin’s lymphoma treated in the city of Medellín, Colombia.
Materials and Methods: A retrospective, descriptive, observational cohort study done in a highly complex institution from 2015 to 2018 in patients with a diagnosis of Hodgkin’s lymphoma who received cisplatin-based chemotherapy. The sample was calculated using the information collected in the medical records. Absolute and relative frequencies were estimated to summarize the qualitative variables, and standard deviation or interquartile ranges for the quantitative variables.
Results: Eighty-one patients treated were included. The median age was 36 years. The median value of creatinine and urea nitrogen was 0.76 and 13.2 mg/dL, respectively. Additionally, the median hemoglobin was 11.9 g/dL, the leukocyte value was 6100/mm3 and platelets 280,000/mm3. It was observed that 32 (39.5%) patients had anemia, 23 (28.3%) concomitant infection, 9 (11.1%) acute renal failure, and 11 (13.5%) died.
Conclusions: Cisplatin treatment is associated with different adverse reactions and toxicity, in the present study it was possible to identify these effects of cisplatin in the therapy for Hodgkin’s lymphoma and, in addition, the epidemiological profile of patients with this disease.


REFERENCES

  1. Lo Presti AC, Aular Y, Morales L, Payares E. Reaccionesadversas renales y hematológicas producidas por cisplatinoy carboplatino con concurrente radioterapiaen pacientes con cáncer de cuello uterino. Salus 2008;12 (1): 17-22.

  2. Guan J, Zhang Y, Li Q, Zhang Y, Li L, Chen M, et al. A metaanalysisof weekly cisplatin versus three weekly cisplatinchemotherapy plus concurrent radiotherapy (CRT) foradvanced head and neck cancer (HNC). Oncotarget 2016;7 (43): 70185-70193. doi: 10.18632/oncotarget.11824.

  3. San Martín R, Suárez E, Olfos P, Escudero P, Rojas L, LarraguibelR, et al. Cáncer cervicouterino en estadio IB2: tratamientocon radioquimioterapia concomitante y cirugía. RevChil Obstet Ginecol 2003; 68 (6): 447-457. doi: 10.4067/S0717-75262003000600001.

  4. Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD,Milowsky MI. A Systematic review of strategies to preventcisplatin-induced nephrotoxicity. Oncologist 2017; 22 (5):609-619. doi: 10.1634/theoncologist.2016-0319.

  5. Sánchez-González PD, López-Hernández FJ, López-Novoa JM, Morales AI. An integrative view of thepathophysiological events leading to cisplatin nephrotoxicity.Crit Rev Toxicol 2011; 41 (10): 803-21. doi:10.3109/10408444.2011.602662.

  6. Xiang X, Guo C, Tang C, Cai J, Dong Z. Epigenetic Regulationin kidney toxicity: insights from cisplatin nephrotoxicity.Semin Nephrol 2019; 39 (2): 152-58. doi: 10.1016/j.semnephrol.2018.12.005.

  7. Quintanilha JCF, Saavedra KF, Visacri MB, Moriel P, SalazarLA. Role of epigenetic mechanisms in cisplatin-inducedtoxicity. Crit Rev Oncol Hematol 2019; 137: 131-42. doi:10.1016/j.critrevonc.2019.03.004.

  8. Sorigue M, Sancho JM, Pineda A, Garcia O, Lopez D, MorenoM, et al. Incidence and prognostic significance of nephrotoxicityin patients receiving eshap as salvage therapy forlymphoma. Leuk Res 2017; 58: 98-101. doi: 10.1016/j.leukres.2017.05.001.

  9. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V,Kouroukis CT, et al. Randomized comparison of gemcitabine,dexamethasone, and cisplatin versus dexamethasone,cytarabine, and cisplatin chemotherapy before autologousstem-cell transplantation for relapsed and refractory aggressivelymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32(31): 3490-6. doi: 10.1200/JCO.2013.53.9593.

  10. Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosisof Hodgkin lymphoma in the modern era. Br J Haematol2019; 184 (1): 45-59. doi: 10.1111/bjh.15614.

  11. Manohar S, Leung N. Cisplatin nephrotoxicity: a review ofthe literature. J Nephrol 2018; 31 (1): 15-25. doi: 10.1007/s40620-017-0392.

  12. Oosting SF, Chen TWW, Huang SH, Wang L, Waldron J,Gilbert R, et al. A comparison of weekly versus 3-weeklycisplatin during adjuvant radiotherapy for high-risk headand neck cancer. Oral Oncol 2016; 59: 43-49. doi: 10.1016/j.oraloncology.2016.05.016.

  13. Herrero D, Marí A, Merino M, Boquera ML, Jiménez V. Perfilde toxicidad y adherencia del esquema farmacoterapéuticogemcitabina-carboplatino en cáncer de pulmón nomicrocítico. Farm Hosp 2011; 35 (6): 298-304.

  14. Godoy Torso N, Pereira JKN, Visacri MB, VasconcelosPENS, Loren P, Saavedra K, et al. Dysregulated microRNAsas biomarkers or therapeutic targets in cisplatin-inducednephrotoxicity: A Systematic review. Int J Mol Sci 2021; 22(23): 12765. doi: 10.3390/ijms222312765.

  15. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K,Noronha V, Adelstein D, Van Gestel D, Vermorken JB.Low-dose vs. high-dose cisplatin: lessons learned from 59chemoradiotherapy trials in head and neck cancer. FrontOncol 2019; 9: 86. doi: 10.3389/fonc.2019.00086.

  16. Sleijfer DT, Meijer S, Mulder NH. Cisplatin: a review ofclinical applications and renal toxicity. Pharm Weekbl Sci1985; 7 (6): 237-44. doi: 10.1007/BF01959196.

  17. Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, DolanME. Genetic and modifiable risk factors contributing tocisplatin-induced toxicities. Clin Cancer Res 2019; 25 (4):1147-1155. doi: 10.1158/1078-0432.CCR-18-2244.

  18. Desilets A, Adam JP, Soulières D. Management of cisplatinassociatedtoxicities in bladder cancer patients. Curr OpinSupport Palliat Care 2020; 14 (3): 286-92. doi: 10.1097/SPC.0000000000000505.

  19. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity:a review. Am J Med Sci 2007; 334 (2): 115-24.doi: 10.1097/MAJ.0b013e31812dfe1e.

  20. Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD,Milowsky MI. A systematic review of strategies to preventcisplatin-induced nephrotoxicity. Oncologist 2017; 22 (5):609-619. doi: 10.1634/theoncologist.2016-0319.

  21. Quintero-Sierra Y, Hernández-Padrón C. Linfoma nohodgkiniano parecido al Burkitt: presentación de uncaso. Rev Cubana Hematol Inmunol Hemoter 2016; 32(2): 265-271.

  22. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecularmechanisms of action. Eur J Pharmacol 2014; 740:364-78. doi: 10.1016/j.ejphar.2014.07.025.




2020     |     www.medigraphic.com